

## HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201735688C) (Incorporated in the Republic of Singapore)

## GRANT OF SHARE AWARDS PURSUANT TO THE HYPHENS SHARE PLAN

The Board of Directors of Hyphens Pharma International Limited (the "Company", and together with its subsidiaries, the "Group") wishes to announce that the Company had, on 15 May 2019, granted share awards ("Awards") to eligible employees of the Group by the allotment and issuance of an aggregate of 430,400 ordinary shares in the capital of the Company pursuant to the Hyphens Share Plan ("HSP").

In accordance with Rule 704(32) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited, the details of the grant of Awards are as follows:-

(a)	Date of grant of Awards:	15 May 2019
(b)	Number of Shares which are the subject of the Awards:	430,400 ("New Shares")
(c)	Consideration payable for grant of Awards	None
(d)	Market price of shares on the date of grant of Awards:	S\$0.20
(e)	Number of Shares which are the subject of the Awards granted to each Director and/or controlling shareholder (and their associates), if any:	None of the shares which are the subject of the Awards were granted to Directors and controlling shareholder (and their associates)
(f)	Vesting period:	All the Awards granted under the HSP have vested immediately on the date of grant.

The New Shares granted shall have a sale restriction moratorium period of 2 years from the date of grant.

Following the allotment and issuance of the New Shares, the total number of ordinary shares in the capital of the Company has increased from 300,000,000 ordinary shares to 300,430,400 ordinary shares.

BY ORDER OF THE BOARD

Lim See Wah

Executive Chairman and Chief Executive Officer

Date: 15 May 2019

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor, DBS Bank Ltd. ("Sponsor") for compliance with the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President. The contact particulars are 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.